Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 7/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14544855 | 0.89 | GAA (0.47) | GAAALDH1A1SMN1; SMN2ACHETDP1 | |
| SCHEMBL27466405 | 0.86 | NAAA (0.55) | GAAACHENAAADGKAFAAH | |
| SCHEMBL3904057 | 0.84 | GAA (0.63) | GAAALDH1A1SMN1; SMN2RECQLTSHR | |
| SCHEMBL28757970 | 0.81 | GAA (0.46) | GAAALDH1A1SMN1; SMN2RECQLTSHR | |
| SCHEMBL12322932 | 0.81 | GAA (0.46) | GAAALDH1A1SMN1; SMN2RECQLTSHR | |
| SCHEMBL16938303 | 0.79 | HPGD (0.46) | GAAALDH1A1RECQLTSHRHPGD | |
| Hydrochloric Acid SCHEMBL713839 | 0.79 | GAA (0.44) | GAAALDH1A1SMN1; SMN2RECQLTSHR | |
| SCHEMBL17994018 | 0.78 | GAA (0.51) | GAAALDH1A1SMN1; SMN2RECQLHPGD | |
| SCHEMBL22971368 | 0.78 | GAA (0.56) | GAAALDH1A1SMN1; SMN2TSHRHPGD | |
| SCHEMBL5208480 | 0.78 | GAA (0.41) | GAAALDH1A1SMN1; SMN2ACHETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119529814-A | Self-generated composite acid fracturing fluid without preparation and application thereof | 中国石油天然气股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-6774231-B2 | BACTERICIDES | PHARMACIA & UPJOHN COMPANY | 2004-08-10 | — | — | US | disclosed |
| EP-1379509-A1 | A METHOD FOR THE PREPARATION OF OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030004160-A1 | Method for the preparation of oxazolidinones | PHARMACIA & UPJOHN COMPANY | 2003-01-02 | — | — | US | disclosed |
| WO-2002085865-A1 | A METHOD FOR THE PREPARATION OF OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004160-A1 | Method for the preparation of oxazolidinones | CYP3A5, OXA1L, OGFOD1 | GAA 2791/4885ALDH1A1 79/4885SMN1; SMN2 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.